Cancer is a genetic disease characterized by a pro gressive accumulation of genomic aberrations that are sometimes augmented by predisposing germline mutations 1 . In the 1970s, Nowell 2 and others proposed that this accumulation of mutations is guided by evo lutionary principles via a process of diversification and selection for mutations that promote tumour cell proliferation and survival. The idea that evolutionary mechanisms underlie cancer progression has become a guiding principle in understanding, predicting, and controlling cancer progression 3 , metastasis 4 , and thera peutic responses 5, 6 . Models of tumour evolution have incorporated advanced evolutionary theory [7] [8] [9] and com plex evolutionary mechanisms that have been revealed by modern genomic technologies 10, 11 . The application of evolutionary principles to cancers has blossomed into a field in its own right, with a rich foundation of theory and methods for interpreting tumour evolu tion 12, 13 . Here, we survey one influential thread: the use of phylogenetics -that is, evolutionary tree building -to understand tumour progression.
Although evolutionary theory has proven to be powerful for understanding cancer progression, evolu tionary processes are quite different in cancers versus in species 14 in ways that are important to phylogenetic inference. These differences manifest in at least four areas: first, the types of aberration that commonly arise; second, the rates of mutation; third, the extent and inten sity of selection; and fourth, the typically high hetero geneity of tumour cell subclones. One frequent feature of cancer evolution is hypermutability 15 , often associated with types of mutation that are rare in species evolu tion. Hypermutability phenotypes include chromosome instability (CIN) phenotypes that are characteristic of p53 dysfunction 16 , microsatellite instability (MIN) 17 , and elevated point mutation phenotypes, such as those arising from dysregulation of the APOBEC family of deaminase proteins 17, 18 . Some variant types, such as copy number variants (CNVs), may be induced by multiple mechanisms -including breakage-fusion-bridge (BFB) cycles, missegregation of chromosomes, and genome doubling -each producing distinct scales and loca tions of aberrations [19] [20] [21] [22] . Other tumourspecific muta tional mechanisms include the following: kataegis 23 , in which single nucleotide variants (SNVs) occur at a high rate in a small chromosomal region; chromothripsis 24 , in which a single chromosome shatters and reassem bles in a seemingly random manner; and chromo plexy 25 , a complex structural variation characterized by chains of BFBinduced chromosome rearrangements occurring in successive mitoses.
Likewise, patterns of elevated SNV accumulation can differ widely by tissue of origin or from patient to patient. Alexandrov et al. 26 characterized dozens of 'mutation signatures' defining the nucleotide biases exhibited in subsets of cancers, some with known environmental triggers 27 , others attributable to spe cific sources of somatic hypermutability 18 , and some of unknown cause. Mechanisms of hypermutability may vary by tumour and over time in ways that are not observed in species evolution 21, [28] [29] [30] [31] . Treatment creates another complication, as chemotherapy or radiation therapy can themselves cause doublestrand breaks in the DNA 32 or other forms of hypermutation 33, 34 
Subclones
Subpopulations of cells in a tumour; the cells in each subclone are almost or completely genetically identical for all measured cancer-related variants.
Hypermutability
An elevated mitotic mutation rate, relative to that in healthy cells; this is often specific to a given mutation type (for example, a single nucleotide variant or a copy number variant).
Intra-tumour heterogeneity
Variation in the genomes of different cells in the same tumour.
Tumour self-seeding
A process by which descendants of cells that escaped the primary tumour re-enter circulation and return to the primary site.
Mathematical model
A formal mathematical abstraction of a physical or biological process, such as a set of evolutionary mechanisms.
The predominant mechanisms of selection in cancers also differ from those in species evolution. Most studies of tumour evolution have assumed selec tion for mutations that promote survival, proliferation, or other phenotypic hallmarks of cancer 36 . Selection, like diversification, can be dynamic, as cell popula tions adapt to or change their microenvironment 11 . However, recent work has suggested that selection often plays only a minor part in tumour evolution, in contrast to its role in Darwinian evolution of species. The repeated observation of substantial intra-tumour heterogeneity 21, [37] [38] [39] [40] [41] [42] [43] [44] runs counter to the idea that only the fittest subclones survive. Some recent studies have sug gested that some tumours evolve by effectively neutral processes without selection, at least pretreatment [45] [46] [47] . It has been suggested that strong versus weak selec tion might be reconciled by a 'punctuated equilibrium' model 9 , in which long periods of slow mutation under weak selection are interrupted by short bursts of rapid evolution under strong selection, although this model cannot explain the evidence for a lack of selection in some tumours 48 . Therapy must also be considered when modelling selection 49, 50 . In contrast to the disagreement about whether tumour evolution is nonDarwinian at the pretreatment stage, there is general agreement that treatment leads to selection which can alter the dom inant clones 10, 14, 34, 51 . Singleagent treatment can lead to relapse 49, 52 by selecting for nonresponsive clones 29, 53 . Durable targeted therapies may require the identifica tion of driver mutations in all tumour subclones and the design of patientspecific drug combinations 8, 11, 54, 55 . High heterogeneity is another characteristic feature of tumour evolution. Higher intratumour hetero geneity has been associated with poorer prognosis 8, [56] [57] [58] and linked with the ability of the tumour to resist immune surveillance and therapy 3, 59, 60 . Progression, metastasis, and therapeutic resistance frequently proceed from clones that were rare at earlier progression stages 41, 43, 49, 61 . Interactions among distinct clones may also drive tumour progression, for example through tumour self-seeding 4, 62 and cooperation between clones 63, 64 . This Review examines one important direction in which evolutionary models are shaping cancer research: the use of phylogenetic methods in interpret ing genomic data from cancers. We specifically seek to provide guidance to the users of phylogenetic methods in cancer research and to those critically reading about those uses, especially those lacking formal training in phylogenetics. To accomplish that, we give a short over view of the field, we review past uses of tumour phylo genetics, and we explain some relevant principles of phylogenetic inference. We conclude with speculation about the challenges and opportunities for realizing the potential of phylogenetics in cancer research.
Overview of tumour phylogenetics
The recognition that cancer is an evolutionary phenom enon led to the insight that computational methods for reconstructing evolutionary processes -that is, phylogenetics -might prove valuable for making sense of tumour progression processes. Tsao et al. were among the first to suggest that variations in micro satellite markers could be used to infer a tree model of the evo lution of tumour cells 65 . The idea was subsequently put into practice for bulk comparative genomic hybridiza tion (CGH) data by Desper et al. 66 . After percolating for a decade within a specialist community of evolution ary and computational biologists, this type of analysis has exploded to become a new field known as tumour phylo genetics, which aims to reconstruct tumour evo lution from genomic variations. In almost all cases, the goal of such work is to produce evolutionary trees, potentially allowing for uncertainty among the space of possible trees explaining a data set 21, 67, 68 . Within that basic framework, tumour phylogenetics encompasses diverse methods. This diversity includes various data types, referring both to the basic study design (crosscohort studies of many tumours, single patient studies of regional bulk genomic assays, or studies of singlecell variability in single tumours) (FIG. 1) and the type or types of genomic data profiled (initially, presequencing marker types such as largescale CGH 66 or fluorescence in situ hybridization (FISH) 69 ; now, pre dominantly nextgeneration sequencing (NGS)derived SNVs 70 or CNVs
71
, and sometimes more exotic variant types such as gene expression, DNA methylation, or histone marks 10, 14, 32, 72, 73 ). The diversity also includes variation by mathematical model; that is, the mathemat ical representation of the kinds of mutational processes one intends to study. The model may capture both the kind of mutations considered (for example, SNVs versus structural variants (SVs) 20, 74 ) and basic questions such as whether those mutations are assumed to be under selec tion 2, 7, 11, 14, 17, 72, 75 or selectively neutral 4, [76] [77] [78] [79] . Furthermore, this diversity of methods includes variation in the algo rithms applied; that is, the computational instructions used to find an optimal tree or trees consistent with both the data and the model. The importance and utility of in silico models to study various phenomena in cancer goes far beyond tumour phylogenetics, and other kinds of models have been reviewed elsewhere 12, 13 . Many of the papers cited therein take a traditional mathematical modelling approach with emphasis on the mathemat ics, on simulation studies, on parameter estimation, and on validating the model. As tumour phylogenetics has gained in popularity, phylogenetics now tends to show up as a small part of highimpact studies. These studies are understandably focused on data sets that were derived from human subjects and were expensive and complicated to collect. One of the main messages of this Review is that when mathematical models are used in these studies, the importance of validating the models against simulated and observed data should not be forgotten.
Most studies of tumour phylogenetics to date have adapted standard algorithms that were developed for species phylogenetics (for example, maximum par simony 21, 61 , minimum evolution 73 , neighbour join ing 71, 80 , UPGMA 21 , or various maximum likelihood or Bayesian probabilistic inference methods 81, 82 ), occa sionally comparing multiple standard approaches in a single study 21, 83 (TABLES 1,2). Only recently have new phylogeny algorithms emerged to deal with the pecu liarities of tumour versus species evolution [84] [85] [86] [87] [88] . In the next section, we survey the diversity of methods avail able, with particular focus on those suited to modern sequencing technologies.
This variety of phylogeny methods has corresponded to a variety of applications. Tumour evolutionary trees, which were once merely conceptual models 2 , are now central in the results of many studies 11 . Early uses of phylogeny methods often focused on applying the new tool of tumour phylogenetics to old problems, such as using evidence of evolutionary selection to separate driver mutations from passenger mutations 29, 50 , or using novel algorithms to find the order and timing of driver mutations [89] [90] [91] or to determine how these driver mutations associate with progression stages 92 . Other key results have emerged organically, for example from studies addressing the still controversial question of whether tumour evolution follows the expectations of classical clonal evolution theory [93] [94] [95] in producing predominantly linear phylogenies 54, 76, 96, 97 , whether it exhibits predominantly branched evolution exemplified by the early divergence of subclones 30, 33, 40, 42, 49, 73, 83, [98] [99] [100] , or whether it occupies some continuum encompassing both extremes in different tumours 34, 101 . Researchers continue to find new applications for phylogeny models, such as the use of phylogenies prognostically to predict the likely future progression of a tumour 43, 58, 85, 92, 102 ; such applications are an evolution of older approaches that have been used to predict progression from simpler measures of tumour heterogeneity 38, 58, 59, [102] [103] [104] [105] . One worrisome trend among these studies is their seemingly conflicting conclusions about the evolution ary trajectories of cancers, such as on the questions of linear versus branched evolution or Darwinian selec tion versus no selection. The distinctions may be traced to differences in the application of phylogenetics, such as looking at distinct marker types (for example, SNVs versus CNVs) or using distinct evolutionary models or phylogeny algorithms. For example, the studies that Nature Reviews | Genetics .
Variations on tumour phylogenetics
Recent years have seen a rapid proliferation of methods for tumour phylogenetics. In this section, we categorize some of the seminal advances made. We can roughly distinguish three classes of method, based on the kind of phylogeny study for which they are designed: cross sectional methods, which use data on many tumours to build trees describing the common progression pathways These studies have some phylogenetic aspects, but do not produce phylogenies as their primary output. § These studies use some of the more important or innovative software packages.
across a population; regional bulk methods, which build trees for single patients through bulk genomic assays of distinct tumour sites or regions; and singlecell methods, which build trees from the celltocell variations in single tumours (FIG. 1) . Not all methods fit neatly within one category, but the categories provide a crude organization for the description of methods below.
Within these highlevel categories, we see a diversity of genomic data types (TABLE 3) , evolutionary models, and phylogeny algorithms. Below, we consider a subset of methods that were of particular importance in intro ducing new techniques to the field or were of unique value to likely users. Cross-sectional tumour phylogenetics. Key ideas behind crosssectional tumour phylogenetics originate in the prephylogenetic work of Fearon and Vogelstein, who proposed that bulk analysis of collections of tumours from multiple patients could allow one to infer the likely orders of aberrations and stages of progression (for exam ple, from adenoma to carcinoma) so that each aberration is associated with progression to a specific stage 93 . They proposed a linear (event 2 follows event 1 follows event 0) model for the progression of colorectal cancer. This Fearon-Vogelstein model, although a simplification 107 , has been highly influential on thinking about tumour evolution. Phylogenetic methods were first brought to the reconstruction of tumour progression pathways by Desper et al., who generalized the Fearon-Vogelstein linear progression model to allow branching in the form of a tree, sometimes called an oncogenetic tree 66 . FIGURE 1a provides an illustration of the onco genetic tree model for interpreting crosssectional data that has come from multiple patients. In the original onco genetic tree model, each tree edge corresponds to a possible aberration with an associated probability of occurrence. Paths in the tree correspond to possible sequences of accumulating aberrations.
Many methods have since applied this basic strategy of inferring trees or graphs of possible progression sequences from combinations of mutations observed across a patient cohort. We refer the reader to a general phylogenetics text 82 for more background on the basic classes of phylo genetic models and algorithms summarized in 66 was a characterbased phylogeny method, meaning that it mod elled evolution from a discrete set of phylogenetic markers (variant loci), and it was specifically a kind of maximum parsimony method, meaning that it was a combinatorial optimization method that sought to explain a data set with the smallest number of distinct mutations possible. Characterbased methods tend to be most informative for reconstructing the sequence of mutations and unobserved ancestral states, but they become computationally infea sible on large marker sets. Parsimony methods are the most computationally efficient of the characterbased methods, but they depend on the assumption that muta tions are rather rare, which is a questionable assumption for tumours. The field later moved largely towards more sophisticated probabilistic characterbased methods 108, 109 , which seek either the most probable tree (the maximum likelihood method) or some measure of the space of possible trees and tree parameters (Bayesian sampling). Compared with the earlier approaches, such models better handle high mutation rates, noisy data, and uncertainty in tree inferences, but can be more computationally demanding than parsimony methods. Beerenwinkel et al. 110, 111 introduced an important class of probabilistic model that enables the joint inference of several possi ble trees for binary mutation data, via the Mtreemix tool, an approach that was later generalized to CNV data 112, 113 and became the basis of the newer Rtreemix package [114] [115] [116] . More recent approaches include making better use of the detailed information specifically offered by DNA sequen cing (for example, as in the RESIC 117 approach and a later pathwaylevel variant 118 ). Algorithmically, most such methods rely on comparatively faster maximum likeli hood techniques 113 . However, more advanced Bayesian models commonly use variants of Markov chain Monte Carlo (MCMC) sampling, which is a statistical technique for exploring the ranges of possible tree models and evo lutionary parameters but at a much greater computational cost than maximum likelihood methods 90, 119 . The recur ring theme of tradeoffs between more realistic and more computationally tractable models has inspired a great deal of research into more exotic algorithmic techniques in this domain 91, 120, 121 . The major alternative to characterbased methods are distancebased methods, which use mutation data to esti mate evolutionary distances between samples, and these distances then serve as the basis for tree inference. Such methods can handle much larger marker sets at the cost of losing the finescale modelling of mutational events achieved by characterbased methods. Desper et al. extended their approach to distancebased methods 122 and later extended those from DNA to RNA expression data 123 . Riester et al. 124 developed a similar approach specifically for RNA sequencing data using minimum evolution phylogenies, which is a distancebased ana logue of parsimony methods. Liu et al. 125 applied cross sectional distancebased methods to CNVs using several offtheshelf distancebased phylogeny tools.
Oncogenetic tree methods in recent years have been primarily used to analyse DNA sequencingderived SNV or CNV data 43, 70, 85 , but they have also been used for methylation data 73, 79 . They have proven to be valuable primarily for the original purpose of identifying com binations and orders of recurring driver mutations. In hindsight, the crosssectional tumour phylogeny methods are domainspecific clustering methods that happen to use phylogenetics tools on the assumption that distinct tumours can share common evolutionary trajectories. However, this was not clear until sequen cing studies revealed both intertumour and intratumour hetero geneity, and this finding is part of the 'evolution' of tumour phylogenetics alluded to in the title of this Review.
Given the diversity of methods available, though, one should be aware that simulation studies 126, 127 have shown that qualitative results may depend considerably on the model used to generate the data. Furthermore, most methods for crosssectional data were developed before the extent of intratumour heterogeneity in observed data was appreciated 37 , and tree inferences from crosssectional data can be unreliable in the presence of intratumour heterogeneity 128 . These latter observations help motivate the trend towards phylogenetic studies of single tumours, discussed below.
Regional bulk tumour phylogenetics. A major step for wards was the recognition that one could produce phylo genies for single patients, initially through sampling multiple regions or tumour sites. One treats each site sequenced as if it were a species and infers a tree con necting those species. FIGURE 1b provides an illustra tion of a regional bulk phylogeny built from samples of multiple tumour sites and multiple regions within a tumour site for a single patient. 133, 135 , and distancebased minimum evolution 85 . An important variation on regional bulk tumour phylogenetics is the combination of phylogenetics with clonal deconvolution from bulk sequence 139 . Here, deconvolution means the inference of clonal sub populations from one or more bulk genomic samples. Numerous tools are now available for clonal decon volution (for example, SciClone 140 , PyClone 141 , and Clomial 142 ). Some tumour phylogeny methods listed in TABLE 1 explicitly depend on clonal deconvolution either as a preprocessing step or integrated into the phylogenetic inference strategy. These include some early approaches to deconvolution that were motivated explicitly by the application to tumour phylogenetics 139 , tumour phylogeny methods such as SCHISM 143 , which require a thirdparty clonal deconvolution program to generate their input data, and tools such as cITUP 144 and LICHeE 132 , which fully integrate deconvolution and phylogenetics into a single inference.
Regional bulk phylogenetics has been used in sev eral seminal studies, building on earlier work on multi region progression without explicit phylogenetics 104 . Early, preNGS examples of true multiregion tumour phylogenetics include the use of microsatellite markers by Khalique et al. 96 and of array CGH (aCGH) by Navin et al. 145 . Regional bulk tumour phylogeny methods using DNA sequencingderived markers have since seen extensive use (TABLE 2) . Many studies that apply regional bulk phylogenetics approaches have relied on standard methods or phylogeny programs derived from species evolution 42, 61, 73, 79, 146 . Others have devel oped custom heuristic phylogeny approaches 28, 50, 98, 147, 148 or relied on manual phylogenylike inferences 33, 52 . Only recently have mature thirdparty tools become available (TABLE 1) and begun to appear in case studies (TABLE 2) . Examples include the studies by Schwarz et al. 43 , which applied the MEDICC software to ovarian tumours to demonstrate that relapse tumours typically show early divergence from the primary tumour, by Sottoriva et al. 47 , which also used MEDICC applied to colorectal tumours, resulting in the 'big bang model' of evolution without apparent selection, and by Sottoriva et al. 59 , which utilized TuMult 129 to help demonstrate the role of intratumour heterogeneity in promoting resistance in glioblastomas.
Single-cell tumour phylogenetics. The advance that most raised awareness of tumour phylogenetics among noncomputational cancer researchers was its appli cation to singlecell data, allowing the generation of a phylo genetic tree based on individual tumour cells extracted from a single patient (FIG. 1c) . Singlecell tumour phylogenetics predates singlecell sequencing (scSeq), as it was applied through various older methods offering more limited profiling of single cells via micro satellite 76 or FISH 69 markers; such approaches remain valuable owing to their ability to examine much larger numbers of cells than scSeq 39, 84, 149 (TABLE 3) . Nevertheless, the introduction of scSeq to tumour phylogenetics by Navin et al. 71 deserves much of the credit for bringing tumour phylogenetics into the mainstream of cancer research. Since that work, methods for and applications of scSeq in tumour evolution have proliferated, along with related analyses on the data needs of robust scSeqbased phylogenetic analysis 150 . The majority of published tools for singlecell phylo genetics are still based on prescSeq technologies 84, 148, [151] [152] [153] , with just a handful having been developed specifically for scSeq. Kim and Simon 89 introduced the muttree program, which uses a custom combinatorial inference to find trees optimized for a specialized probabilistic model that dif fers from the models used by other tools which accept the same input. Ross and Markowetz 154 and Jahn et al. 87 developed sophisticated Bayesian probabilistic models for scSeqderived SNVs, and these models were implemented in OncoNEM and SCITE, respectively. Most applications of scSeq phylogenetics to date have thus relied on tools for general species phylo genetics or on phylogenies that have been manually constructed without an explicit model or algorithm (for example, see REF. 39 ). Navin et al. 71 relied on neighbour join ing 155 , which had earlier been used by Frumkin et al. 76 with microsatellite data, to infer phylogenies from 
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Neighbour joining (NJ) Fast method for phylogenetics by successively refining subtrees, approximating a minimum-evolution tree while allowing a possibility of temporally impossible scenarios
76
Unweighted pair group with arithmetic mean (UPGMA)
Method for hierarchically constructing a tree by successively joining subtrees, yielding fast tree reconstruction but being dependent on the molecular clock hypothesis (that variation accumulates at equal rates in all tree branches)
21

Markov chain Monte Carlo (MCMC)
Class of algorithms that is suitable to many forms of probabilistic model and allows one to explore parameter ranges and uncertainty in assignments, but is generally too computationally costly to use on trees of more than a small number of nodes 87 scSeqderived CNVs. Neighbour joining was also used by Xu et al. 80 for application to renal cancers and by Wang et al. 156 for what was, until recently 157 , the largest scSeq study of tumour evolution.
An illustrative tutorial Data, models, algorithms. As more cancer research groups embrace phylogenetic methods, it becomes important to understand what goes into a phylogenetic Dual loss Dual gain Nature Reviews | Genetics analysis and how to interpret its results. Phylogenetics is a complicated subject for which tools can easily be misused. In this section, we provide guidance to aspiring users of tumour phylogenetics and those who want to read such work critically. Our primary takeaway message is this: there is no such thing as a generically 'correct' approach to phylo genetics. Phylogenetic inference, like many problems in bioinformatics, depends on a model representing the biological processes we seek to explain, a data source that we seek to explain in terms of that model, and an algorithm to fit the data to the model. Effective use of phylogenetics involves making appropriate choices of model, data, and algorithm so that all three are mutually consistent and suited to the question at hand.
To frame this discussion, we present it in terms of a hypothetical research study. Let us suppose we have a general scientific question: what are the common recurring sequences and timings of CNVs over the progression from healthy breast tissue to breast cancer? We further suppose that we have gathered data to address that question: wholegenome DNA sequencing at 50× coverage from 200 single cells from a tumour and matched normal control. We then imagine that we built a phylogeny using an offtheshelf neighbour joining phylogeny program 152 , as was done in several prominent studies 71, 76, 80, 97, 145, 158 . This is a qualitatively similar plan to the pioneering work of Navin et al. 71, 157 . How can we evaluate, and perhaps improve upon, this initial plan?
Is our model consistent with our data? If we carry out the study described above, it will yield a phylogenetic tree, and we can expect that tree to be qualitatively similar to those of Navin et al. 71 and Wang et al. 156 : an early split of clones into ploidy classes (diploid, pseudo diploid, and tetraploid) followed by later separation by more finescale CNVs. This may indeed be the true evolutionary history of the tumour, but we also need to consider that it may be an artefact of the approach. In fact, the study as described will yield this outcome regardless of the actual evolutionary history of the tumour for reasons implicit in the model of evolution that our strategy assumed.
The described approach uses a phylogeny model designed primarily for SNV data; such a model assumes that evolution occurs by mutations independently accu mulating one at a time, with roughly equal rates. This happens to be a reasonable simplification for species evolution 82 , and probably even for tumour evolutionprovided that we are tracking evolution in which SNVs accumulate largely without selection 8, [46] [47] [48] . However, it is a questionable model for CNVs, as CNVs violate the model assumption that changes in distinct vari ant regions accumulate independently; instead, CNVs accumulate at multiple scales, from localized genescale variants to variation at the scale of large chromosome segments, whole chromosomes or even wholegenome ploidy 17, 74, 159 . The mismatch between model and data can lead to discrepancies between evolutionary dis tance measures. For example, a 3 billion bp change induced by a wholegenome duplication will yield the same estimated evolutionary distance as 300,000 inde pendent 10 kb changes, even though genome duplica tions are common events 21, 22, 147, 160 and far more likely to occur than 300,000 independent 10 kb changes. That discrepancy will lead to largescale changes being mis interpreted as being older than they actually are rela tive to localized changes, which could radically skew our trees.
If we recognize this issue, it would be logical to propose that we fix the model. There are models for representing the more complex nature of evolution by CNVs versus evolution by SNVs 51 , and there are some customdesigned phylogeny tools for specific variants of CNV evolution 43, 69, 84, 85, 151, 152 . A Bayesian probabil istic model, as has been used in many tumour phylo geny approaches 47, 79, 86, 135 , can handle arbitrarily complex evolutionary scenarios and is well suited to learning the complicated lineagespecific rate parameters one would need for such a model 78, 101, 152 , given the diversity of CNV hypermutability mechanisms any given tumour might exhibit 20, 25, 94, 161 . Let us suppose, then, that we replace the Euclidean distance model with a Bayesian probabilistic model that captures the multiscale nature of CNV evo lution, thus bringing our model in line with our data. Are we now finished? Aligning algorithm and model. Unfortunately, the change to a Bayesian model is insufficient because we cannot change the model without also changing the algorithm. In principle, one could use neighbour joining with a more nuanced probabilistic model of evolution ary distances. However, a distancebased method such as neighbour joining will work poorly if we lack large numbers of mutations of each type to average out uncer tainty over the mutation frequencies and relative orders, and will therefore be likely to fail for important but rarer CNVs, such as ploidy changes. Figure 2 | Some challenges in synchronizing data, models and algorithms when applying tumour phylogenetics to a scientific question. An illustration of a hypothetical scenario described in the main text, in which we seek to infer a phylogenetic history of copy number variant (CNV) events in the progression of a single tumour. Each tree shows the potential evolution of genomic copy number profiles for a set of observed clones (blue lines) and computationally inferred intermediate states (red lines) for a single tumour. a | The hypothetical 'true' tree describing the evolution of a set of clones from a diploid root via a series of CNVs: gain or loss of copy number in a localized region, as well as whole-genome duplication, leading to a doubled copy number genome-wide. b | Incorrect inference due to the use of a model designed for single-base changes, leading to a substantially incorrect phylogeny involving various biologically 'impossible' evolutionary events, such as partial (non-integer) gain, loss, or whole-genome duplications, leading to fractional copy numbers. c | Improved but still inaccurate inference after correcting to an evolutionary model cognizant of the type of variation occurring with CNVs; this eliminates impossible events and leads to a more accurate tree topology, but still fails to identify the correct tree because the analysis is using an algorithm that identifies biologically plausible but still sub-optimal phylogenies for this kind of evolutionary model. d | Still inaccurate inference after changing to a more sophisticated model and algorithm that are well suited to CNV evolution but make it impractical to use single-cell sequence data; this forces a change to a bulk genomic data type, leading to inadequate sampling of extant clones to capture the rapid mutation process typical of CNV-driven evolution and observed in the true tree.
◀
Recognizing that problem, we can adopt a more appropriate algorithm for a probabilistic model, such as the MCMC approach of the BitPhylogeny program 86 . Although other classes of algorithm can be used with such probabilistic models 108, 112, 113, 143, 162, 163 Aligning model and data. Unfortunately, the algorithm change is insufficient, because in synchronizing our algorithm to our model, we selected an algorithm that is not appropriate to our data. Algorithms, like models, carry assumptions and limitations. One limitation of MCMC is computational cost 82 : the number of steps for which one must run an MCMC algorithm to get accurate results generally grows exponentially with the number of species (or cells) in the data. This limita tion is perilous to the novice user because an MCMC algorithm can still generate a tree as an output, even if it has not run for long enough to identify the right tree. MCMC phylogeny algorithms were therefore traditionally used only for the order of 10-20 species, although somewhat larger numbers are now possible 85 . Stateoftheart Bayesian methods in tumour phylo genetics are commonly accelerated with a technique called approximate Bayesian computation (ABC) 164 , as used in two recent investigations 47, 79 ; with this technique, one accelerates sampling by collapsing sets of solutions that appear to be similar by one or more summary stat istics. However, the curse of exponential blowup (in which the number of possible trees an algorithm must consider grows exponentially with the number of 'spe cies' they contain) is that better algorithms will allow us only a few more species, not the orderofmagnitude increase we need to handle 200 cells. In short, the algo rithm we have chosen is probably unsuitable for our singlecell data. A logical next step, then, would be to ask whether we might use a different kind of data more appropri ate to our approach. There are other marker types that we could consider -such as SNVs 87, 154 , expression 123 , methylation 73 , or microsatellites 165 . However, as we are interested in evolution by CNVs, we must keep the marker type unchanged and instead change only the study design. We might propose to use a regional bulk method, replacing our 200 single cells with bulk sequencing of 10 regions from each of 20 tumours. Each of the twenty resulting trees is on a scale an MCMC sampler can handle. Similar regional MCMC strategies for regional bulk sequencing have yielded important insights into tumour evolution in prior studies 47, 59, 79 and have been used successfully for CNV data 86, 129 . We will then have a model appropriate to our data, an algorithm appropriate to our model, and a data set appropriate to our algorithm, harmonizing the three components of our method. Are we now finished?
Aligning method and questions. We are unfortunately still not finished because by changing the data collec tion strategy to smaller sets of 'species' per tree, we have ended up with data sets that are too small to resolve the finescale trajectories of CNV evolution. Most solid tumours have chromosome replication defects that lead to rapid accumulation of CNVs 20 , and progres sion can happen via clones that are minor or rare in the earlier tumour stages 11, 41, 50, 53, 54, 166, 167 and that may lay dormant through much of the clinical progression 168 . We can expect that there are too many CNVs among ten tumour regions to have hope of resolving the orders or timings of CNV events 157 . Our study design might be fine for other questions about CNV evolution, but not for the question we are asking. We still have not man aged to find a model, algorithm, and data source that are consistent with one another and with the question we are asking.
FIGURE 2 provides a simplified overview of the pitfalls in this process, as we seek to infer a true tree (FIG. 2a) but struggle with erroneous inferences induced by a mis match between the evolutionary model and data type (FIG. 2b) , between the algorithm and the model (FIG. 2c) , and between the data type and the research question (FIG. 2d) .
That does not mean that we are out of options. We could try a wholly different approach, perhaps revert ing to our original scSeq study design but using a parsi mony model with a faster algorithm that might be better able to handle the scale of data. That is essentially what was done in a recent scSeq study of breast cancer 157 . TABLES 1,2 give examples of available methods and prior studies that may be helpful for finding an existing tool or strategy that has been successfully applied to simi lar questions. We could try to bring in more exotic algorithms (for example, integer linear programming (ILP) 120, 131, 144, 169 ) or completely different marker types (for example, FISH 69, 84, 151, 152 ). However, we should be aware that we might run through every existing option for a model, an algorithm, and the data type and still fail to find a combination that is mutually consistent and appropriate to our questions. What, then, is the cancer researcher to do?
A final important point is that posing a computa tional problem is not the same thing as solving it, even if we have perfect data and a perfect model of the relevant biological mechanisms. Many reasonable phylogenetics problems are classified as 'intractable' (REF. 170 ), which informally means that for even moderately large data sets, we may not have any method for finding a good tree efficiently. Often, we will need to develop new computa tional theory to find an adequate explanation of the data within the models of evolution that we believe describe them. The answer to the question above -what, then, is the cancer researcher to do? -is often to recognize that there is no standard offtheshelf technique available for many important questions and that developing one is a research problem which will require time and signifi cant expertise in computational biology. BOX 1 provides a few examples of important unsolved methodological problems in tumour phylogenetics.
Conclusions and discussion
The use of phylogenetic techniques in cancer research is growing, as is evidenced by the large body of work com pleted in the past 3 years and referred to herein. Studies of cancer phylogenetics have advanced far beyond the theoretical evolutionary model of Nowell 2 to reveal the enormous complexity of the actual processes of tumour evolution 14, 20, 26, 171 , and to uncover the hetero geneity of those processes both patient to patient 101, 110, 172 and lin eage to lineage in a single patient 3, 8, 21, 40, 73, 145 . Such studies have revealed mechanisms underlying this hetero geneity 21, 85, 145, 173 , the dynamics by which these mecha nisms themselves evolve over tumour progression 47 , and possibilities for novel prognostic indicators 43, 56, 57, 105 . As our knowledge of tumour evolution has expanded, tumour phylogenetics has itself evolved from a new tool for asking old questions, such as distinguishing driver from passen ger mutations 13, 174 , to a source of new questions on topics such as how the evolutionary landscapes of tumours are shaped by environmental factors 16 ,21,26,61 and treatment 32 and how they can reveal the past and possibly the future of the progression of a tumour [27] [28] [29] [30] 47, 59 in ways that are tangential to the specific driver mutations dominant in a given tumour at some time. In this Review, we have sought to survey key methods used and results obtained to date and to provide insight into how best to harness phylogenetic tools for new applications. We conclude by considering where tumour phylogenetics might go next.
Most uses of tumour phylogenetics to date have been in retrospective studies; a major opportunity is moving to prospective studies in research clinics. Looking ahead to this opportunity, we consider what happened in clin ical cancer research with the advent of gene expression microarrays and NGS. Both technologies were expected to have an impact on cancer diagnosis and treatment, but they have had different outcomes. Gene expression microarrays were shown to have prognostic value in hundreds of research studies, but are not currently widely used in the clinic. By contrast, NGS is being used in the clinic and has led to the phenomenon of 'tumour boards' formed by multidisciplinary scientists and clinicians who study mutation profiles, determine which mutations are 'actionable' on the basis of approved drugs, and develop 'precision medicine' treatment plans. We hypothesize that the difference is primarily due to the type of output that these two technologies produce. NGS generates lists of discrete mutations that can be validated and evaluated individually. By contrast, microarrays yield patterns of expression changes, sometimes called gene expression signatures, that are conceptually similar to the nucleo tide variant mutational signatures of cancer genomes 26 . Similarly, so far the prognostic value from tumour phylo genetics has come from analysing the patterns of evolution 43, 58 , not from analysing discrete events. Tumour phylogenetics is far from achieving the reproducibility that is needed for clinical work. The field will need to overcome resistance to complex data and dynamic analysis, and must develop principled, robust methods of analysis implemented in software that is used in many laboratories. Tumour phylogenet ics is itself evolving, but not as quickly as biotechnolo gies to measure aberrations in tumours. In the future, new phylogeny methods will need to be tested on more data sets and compared head to head. The headtohead comparisons will be very complicated if new methods address one of the key unsolved problems in the field: the integration of different data types beyond CNVs and SNVs
. The analysis methods that are deemed most fit will be selected by more research groups and gain wider usage. After some specific methods are used in hundreds of studies, we hope that the results will be sufficiently robust and interpretable to aid in patient prognosis and treatment planning. Similarly, clinicians interpreting phylogenetic analyses should insist that dif ferent methods be tried and that results are actionable only when different methods of analysis lead to the same qualitative understanding of a patient's tumour 68, 106 . Finally, one cannot comprehensively discuss the future prospects of tumour phylogenetics without considering the education of cancer researchers, or bio medical researchers in general. We have provided
Box 1 | Outstanding problems in tumour phylogenetics
Novel or heterogeneous data sources There are many tumour phylogeny methods for common forms of DNA variation (such as single nucleotide variants (SNVs) and copy number variants (CNVs)), some methods for other genomic data (for example, karyotypes, expression data or methylation data), and a few methods integrating multiple forms of data 29, 73 . The field is just beginning to make sense of other sources of information, such as spatial distributions of cell populations 70, 79, 83 , and to make productive use of heterogeneous data 10, 134 .
Comprehensive evolutionary models
We are currently lacking the quantitative models that are required for phylogenetic inference of complex evolutionary events, particularly for recently discovered mechanisms such as chromothripsis or kataegis. However, models are also lacking even for SNVs, which exhibit nuanced combinations of mutational signatures 26, 27 and selective pressures 8 that vary by tumour type, patient, and time 9, 21, 48, 146, 175 and may require extensive sampling to estimate 46 .
Tumour-specific phylogeny algorithms
Most tumour phylogeny work to date has relied on a handful of conventional phylogeny algorithms (neighbour joining, maximum parsimony, maximum likelihood or Markov chain Monte Carlo), and it remains unclear which, if any, are sufficiently accurate for tumour evolution for any given data type and tumour type. Phylogenies including more exotic tumour-specific mechanisms will require new classes of algorithms, which is a largely unexplored topic.
Beyond 'species' trees
Models drawn from species trees themselves may be inadequate descriptions of clonal evolution of tumours 10 for such reasons as cooperation between clones, seeding of metastases by multiple clones, reseeding of primary tumours 8 , or co-evolution with the microenvironment 176 . More specialized tree models, generalizations to non-tree-based evolution, and methods informed by more sophisticated population genetics and ecological models are just beginning to emerge 47 .
Statistical analysis, study design and reproducibility
Few studies examine enough subjects to draw statistically sound conclusions in the presence of extensive inter-tumour heterogeneity 14 , particularly for single-cell sequencing studies, which usually involve at most a few tumours 150 . Questions that depend on finding reproducible features across many tumours -for example, whether tumour evolution is linear or branched, or whether it branches early or late -have largely been addressed anecdotally rather than by adequately powered analyses. There are currently no accepted methods to judge whether a phylogenetic tree provides a well-supported fit to a single tumour 86, 89 . The field has barely explored the problem of how to plan a study to ensure that informative and robust phylogenetic tree building will even be possible.
guidance on how someone new to tumour phylogenet ics might evaluate and carry out research in this domain, but such basic principles can only go so far. As we have shown here, effective use of even welldeveloped tools requires some understanding of their mathematical and algorithmic underpinnings. Finding or developing the appropriate phylogeny tools for a given application will often involve difficult problems of model selection (as reported by Yuan et al. 86 ) and algorithm design that lie far beyond what we can discuss here. Furthermore, by the time one has identified a study cohort and planned data collection, the questions it is possible to ask with these tools are already constrained. In addition, there are limits to what one can ask at all with the available com putational tools. Some important questions require new tool development or theoretical advances before they can be answered. It is crucial to involve computational biologists early in the study design phase, to ensure that it will be possible, in principle, for the study to resolve the questions that motivate it. More specifically, these specialists can determine that analysis tools appropriate to the data, evolutionary models, and questions do cur rently exist or that there is a plausible path to developing appropriate tools. Even the casual user must be able to recognize these situations. Actually posing and solv ing new datadriven questions, within the constraints of the limits of biotechnology and human cohorts, are demanding skills that will be needed by the leaders of future research efforts in cancer evolution. Few life sci entists today are adequately trained in the fundamentals of computational thinking to handle these questions, and not many computational scientists are adequately trained in the challenges of genomic data and research involving human subjects. If we are to realize the full potential of cancer phylogenetics, we will require a sea change in the training of cancer researchers to inculcate a sophisticated understanding of how to reason about datadriven research. The required changes in educa tion practice are likely to face institutional obstacles, but resolving them is as important to the future pro gress of cancer research as any purely scientific question considered here.
